• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Vaccines / HPV / Gardasil / Silgard / Fast-Tracking Oncology Drugs Questioned

Fast-Tracking Oncology Drugs Questioned

March 30, 2011 By Jonathan 2 Comments

MedPage Today

By Kristina Fiore, Staff Writer, MedPage Today
Published: March 27, 2011
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner

Cancer drugs rushed to the market via the FDA’s accelerated approval process often languish in confirmatory trials, agency researchers say.

Out of 47 indications granted fast-track status, benefits have not yet been confirmed in 21, mostly because trials are ongoing, according to John R. Johnson, MD, of the FDA’s oncology drugs office, and colleagues.

“Lack of due diligence in conducting confirmatory trials is a serious concern that has threatened the continuation of the accelerated approval process,” they wrote online in the Journal of the National Cancer Institute.

They noted that the Food, Drug, and Cosmetic Act of 2007 gives the FDA authority to levy penalties of up to $10 million on pharmaceutical companies for not completing trials for fast-tracked drugs quickly enough.

The accelerated approval process was established in 1992 for drugs that seemed more beneficial than existing therapies for life-threatening diseases, largely motivated by the emergence of HIV/AIDS.

Accelerated approvals may be granted on the basis of surrogate endpoints such as disease-free survival or time to progression. But to keep the approval, sponsors must conduct confirmatory trials that document the drugs’ actual benefit for overall survival or other more patient-centered outcomes.

For their review, the FDA researchers looked at all of the oncology products fast-tracked between Dec. 11, 1992 and July 1, 2010.

A total of 35 products were fast-tracked for 47 new indications; for 26 indications, the benefits were ultimately confirmed.

The median time to official full approval following the accelerated approval was 3.9 years, and the mean time was 4.7 years, “which represents substantial time savings in terms of earlier availability of drugs to patients,” the researchers wrote.

The three longest stretches between accelerated approval and successful conversion to regular approval were 12.6 years, 9.7 years, and 8.1 years.

But the analysis found that the benefit had not been confirmed in 21 new indications.

For three drugs — amifostine, gemtuzumab ozogamicin, and gefitinib — trials were completed and they failed to show benefit.

The researchers noted that it took about 10 years to find that amifostine and gemtuzumab ozogomycin weren’t clinically beneficial.

Read Full Article…

[Note from SaneVax: Gardasil was approved via the accelerated approval process even though a safe and effective means of preventing invasive cervical cancer already existed. Gardasil clinical trials also used a surrogate endpoint (a questionable surrogate endpoint, in our opinion). So, a new drug (vaccine) was approved when it did not qualify for fast-track approval — because of the nature of cervical cancer progression, it will take decades to prove whether it is effective or not. Meanwhile, healthy young women are injected with an unproven substance that may or may not do anything for them. Adverse events and deaths continue to be reported after vaccination. Worse than that, because the label says ‘vaccine’ the manufacturer has virtually blanket immunity from liability. This is not acceptable.

When it comes to using any drugs, yes-vaccines are drugs, on healthy people – NO RISK IS ACCEPTABLE.]

Related

Filed Under: Gardasil / Silgard, Pharmaceuticals, SANE Vax in the News, Vaccine Marketing, Vaccine Related Research Tagged With: Cervical Cancer HPV, Gardasil, oncology drugs questioned, Sane Vax, Vaccine Adverse Reactions

Trackbacks

  1. Gardasil Vaccine Survivors in Ireland Launch Support Group | Health Exchange says:
    June 6, 2015 at 7:30 pm

    […] the limited safety testing that took place as a result of this “life-saving vaccine” being fast-tracked through the regulatory approval process. HSE did not inform parents that Gardasil contains genetically […]

    Reply
  2. Gardasil Survivors in Ireland Launch Support Group - 2 Real News says:
    June 7, 2015 at 9:53 am

    […] dads have in numerous cases indicated that the ladies are not able to continue their education inschool. Since of the nature of the chronic health problems, Irish doctors and consultants are unable to provide any […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Anna from Avila

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

the canary party

Gardasil: I am not a coincidence

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in